Pricing Log in Create free account
Saturday 17 October 2026 Export BIO’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

BIO Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 19.0%, free cash flow fell 6.06% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

353.70 11.12 −3.05%
Market cap
$9.8B
P/E
42.5×
Fwd P/E
35.4×
Dividend yield
—
F-score
5/9
Altman Z
3.20
Beneish M
−2.29
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.35
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — — — — — 1 — — — — —
Insider Ownership 33.30%

Capital & Financial Ratios $m

Market Cap 9,760.00
Revenue 2,589.30
Net Income 318.30
Free Cash Flow 353.10
Net Debt (414.80)
Current Ratio 3.14 (at or above 1.5: strong)
Debt/Equity 0.17 (at or below 0.5: strong)
P/E ratio 42.46 (above 35: high)
Fwd P/E 35.40 (above 35: high)
P/S ratio 3.65
P/B ratio 1.32
Past 5Y EPS Growth (26.08%) (below 0%: weak)
This Y EPS Growth (1.71%) (below 0%: weak)
Next Y EPS Growth 5.08%
Next Y revenue growth (0.55%) (below 0%: weak)
Next 5Y EPS Growth 5.06%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.5×, against a ten-year median of 3.6×; over the ten years it ranged from 1.7× in 2016 to 7.9× in 2021.
P/E against its own 10 years 70.70%
10-year low 10-year high
P/S against its own 10 years 46.92%
10-year low 10-year high
P/B against its own 10 years 26.83%
10-year low 10-year high
EV/Sales against its own 10 years 47.07%
10-year low 10-year high
EV/FCF against its own 10 years 14.57%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,613 1,665 1,541 1,619
Receivables 489 453 461 442
Inventory 781 760 741 781
Other 26 31 28 32
3,048 3,030 2,906 3,021
2023 2024 2025 Q'26
Payables 145 122 129 144
ST’ Debt 1 1 1 401
Other 162 147 142 159
523 468 517 961

Compound Annual Growth %

10y 5y 3y
Sales 2.49% 0.29% (2.68%)
Cash Flow 11.07% (1.87%) 39.89%
Earnings 21.41% (27.58%) 0.00%
Book Value 11.59% (5.48%) (8.14%)

Revenue $m

Mar Jun Sep Dec Year
’26 592 651 — — —
’25 585 652 653 693 2,583
’24 611 639 650 668 2,567
’23 677 681 632 681 2,671
’22 700 691 681 730 2,802
’21 727 716 747 733 2,923
’20 572 537 647 790 2,546
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 108 99 — — —
’25 130 117 121 165 532
’24 70 98 164 124 455
’23 98 98 98 81 375
’22 50 53 11 80 194
’21 114 155 230 171 669
’20 63 92 136 294 585
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 78 67 — — —
’25 96 71 89 119 375
’24 30 55 123 81 290
’23 62 63 54 39 218
’22 17 36 (17) 43 80
’21 94 131 196 115 536
’20 41 74 116 249 480
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (19.55) 13.85 — — —
’25 2.29 11.67 (12.70) 26.65 27.85
’24 13.45 (76.26) 23.34 (25.57) (65.36)
’23 2.32 (39.59) 3.64 12.14 (21.82)
’22 (112.57) (31.12) (5.52) 27.78 (121.79)
’21 32.38 30.32 129.96 (52.59) 140.56
’20 22.72 32.15 43.64 27.81 126.20
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 122.03 181.87 220.05 223.89 309.38 545.00 344.63 261.59 262.12 211.43

Analyst estimates 2026–2028

Powerpack
High 184.89 273.87 345.15 376.43 648.39 832.70 752.17 509.62 387.99 373.69
People
People Employees 8,250 3,270 8,260 8,120 8,000 7,900 8,200 8,030 7,700 7,450
Revenue/emp, $m 0.25 0.66 0.28 0.28 0.32 0.37 0.34 0.33 0.33 0.35
Income, $m
Income, $m Revenue 2,068 2,160 2,289 2,312 2,546 2,923 2,802 2,671 2,567 2,583
Gross margin, % 55.05 54.98 53.43 54.38 56.48 56.05 55.93 53.42 53.73 51.87
EBT 42 98 513 2,261 4,918 5,449 (4,704) (850) (2,342) 996
EBT margin, % 2.01 4.53 22.39 97.81 193.19 186.45 (167.88) (31.82) (91.27) 38.54
Net income — — — — — — — — — —
Depreciation — — — — — — — — — —
Per share, $
Per share, $ Revenue 70.25 72.84 76.73 77.46 85.52 97.97 94.08 91.45 90.97 94.75
Earnings 0.96 3.87 12.10 58.93 127.86 142.33 (121.79) (21.82) (65.36) 27.87
Cash flow 7.34 3.51 9.57 15.34 19.65 22.44 6.53 12.84 16.13 19.52
Capex (4.80) (3.88) (4.21) (3.00) (3.53) (4.48) (3.83) (5.36) (5.87) (5.78)
Free cash flow 2.54 (0.37) 5.36 12.34 16.12 17.96 2.70 7.48 10.27 13.74
Book value 87.61 98.81 134.75 192.84 331.90 458.76 322.82 299.26 232.84 273.40
Shares, m 29 30 30 30 30 30 30 29 28 27
Valuation, ×
Valuation, × P/E 190.53 62.54 19.07 6.28 4.56 5.30 0.00 0.00 0.00 10.84
P/S 2.60 3.31 3.03 4.78 6.82 7.71 4.49 3.59 3.61 3.20
P/B 2.09 2.44 1.72 1.92 1.76 1.65 1.31 1.10 1.41 1.11
EV/Sales 2.41 3.16 2.85 4.48 6.43 7.42 4.28 3.43 3.43 3.07
EV/FCF 66.48 (619.06) 40.74 28.13 34.11 40.20 142.98 41.59 30.19 21.03
Cash, $m
Cash, $m Operating cash flow 216 104 285 458 585 669 194 375 455 532
Capex (141) (115) (126) (90) (105) (134) (114) (156) (165) (157)
Free cash flow 75 (11) 160 368 480 536 80 218 290 375
Balance, $m
Balance, $m Working capital 1,373 1,474 1,573 1,275 1,508 1,310 2,589 2,526 2,563 2,389
Total debt 434 435 439 440 14 11 1,198 1,200 1,202 1,203
Net debt (410) (326) (411) (680) (983) (864) (598) (413) (463) (338)
Shareholders’ equity 2,579 2,930 4,020 5,755 9,880 13,685 9,615 8,741 6,569 7,454
Returns, %
Returns, % ROA 0.69 3.01 7.40 25.83 36.36 27.65 (23.18) (4.94) (17.03) 7.62
ROIC 1.61 2.86 (1.79) 2.83 2.96 2.44 3.34 2.54 2.75 0.41
ROE 1.03 4.44 10.52 35.98 48.79 36.11 (31.14) (6.94) (24.09) 10.84
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Bio-Rad Laboratories, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PEN Penumbra, Inc. $12.7B 78.4× 63.5× +14.90% (above 0%: growing) −24.79% (below 0%: shrinking) +10.81% (above 0%: growing) 67.93% 10.52% Compare
SNN Smith & Nephew SNATS, Inc. $12.2B 35.4× 18.6× +7.99% (above 0%: growing) −14.23% (below 0%: shrinking) +293.94% (above 0%: growing) 69.42% 0.00% Compare
GMED Globus Medical, Inc. $10.6B 19.3× 20.3× +5.94% (above 0%: growing) −25.33% (below 0%: shrinking) +571.30% (above 0%: growing) 69.42% 23.10% Compare
BIO.B Bio-Rad Laboratories, Inc. $10.3B 43.7× — −0.09% (below 0%: shrinking) +19.02% (above 0%: growing) −6.06% (below 0%: shrinking) 53.12% 11.15% Compare
GKOS Glaukos Corporation $9.8B — (loss-making) — (loss-making) +49.54% (above 0%: growing) n/m +211.83% (above 0%: growing) 81.67% (9.30%) Compare
BIO Bio-Rad Laboratories, Inc. $9.8B 42.5× 35.4× −0.09% (below 0%: shrinking) +19.02% (above 0%: growing) −6.06% (below 0%: shrinking) 53.12% 11.15%
PODD Insulet Corporation $9.6B 26.4× 24.7× +23.51% (above 0%: growing) +328.13% (above 0%: growing) −70.51% (below 0%: shrinking) 70.18% 16.18% Compare
BRKR Bruker Corporation $8.6B — (loss-making) 55.7× +5.15% (above 0%: growing) n/m +28.63% (above 0%: growing) 49.61% (7.79%) Compare
HAE Haemonetics Corporation $5.5B 57.7× 18.0× +5.60% (above 0%: growing) +2.86% (above 0%: growing) +220.38% (above 0%: growing) 59.76% 16.93% Compare
Median of peers $10.0B 39.6× 22.5× +6.97% −5.69% +120.23% 68.68% 10.84%

All 149 Medical Devices stocks →

Bio-Rad Laboratories, Inc. (BIO) key facts

  • Strength: Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
  • Bio-Rad Laboratories, Inc. (BIO) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, BIO traded at $353.70, a market capitalization of $9.8 billion.
  • Return on equity was 10.8% and debt-to-equity 0.17.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 3.20 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Bio-Rad Laboratories, Inc. (BIO) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/BIO · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com